07.16.21
Headquarters: Ingelheim, Germany
twitter.com/Boehringer
www.boehringer-ingelheim.com
Headcount: 51,944
Year Established: 1989
Pharma Revenues: $17,705 (+3%)
Net Income: $3,761 (+13)
R&D: $3,696 (+7%)
TOP SELLING DRUGS
In 2020, Boehringer Ingelheim’s pharma revenue rose 3% to $17,705 million despite the Covid-19 pandemic. The company’s research focuses on cardiovascular and metabolic diseases, oncology, respiratory diseases, immunology, diseases of the central nervous system (CNS) and retinal health. Its major emphasis is on the development of medicines and new approaches and therapies to prevent, detect and treat chronic diseases.
The type 2 diabetes medicine jardiance, which also reduces the risk of cardiovascular diseases for type 2 diabetics with pre-existing cardiovascular conditions, was the group’s biggest selling Human Pharma product for the second consecutive year.
At the same time, ofev, which is used for the treatment of the rare respiratory disease idiopathic pulmonary fibrosis and increasingly also in a further indication—systemic sclerosis with interstitial lung disease—registered especially strong growth.
Three other products also played a significant role in Boehringer’s success: Spiriva, which is used for the treatment of chronic obstructive pulmonary disease (COPD) as well as asthma, Trajenta, which is used for treatment of type 2 diabetes, and pradaxa, which is used to prevent strokes in patients with atrial fibrillation and for the prevention and treatment of thromboembolic disorders.
In positive pipeline news, the European Commission approved an additional indication for Nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). The approval came after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.
Also, the U.S. FDA recently granted Fast Track status to Boehringer and Zealand Pharma’s GLP-1/glucagon dual antagonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH). BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis with and without diabetes. The primary endpoint of the trial is the histological improvement of steatohepatitis without worsening of fibrosis after 48 weeks of treatment.
Still, not all projects can be completed successfully: In 2020, Boehringer and Bridge Biotherapeutics mutually agreed on the termination of the collaboration on an autotaxin inhibitor for fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IPF).
In 2020, Boehringer reinforced its position in the area of immunoncology therapies by acquiring shares in the Canadian company Northern Biologics Inc., which was subsequently renamed BI IO Canada Inc. The group also expanded its portfolio of collaborations and partnerships: In the past year, Boehringer entered into new partnerships which include relationships with the U.S. firm Mirati Therapeutics, Inc., which is investigating the use of “PAN-KRAS” inhibitors in the fight against tumors, and with the Swiss company Numab Therapeutics AG, with the goal of developing and commercializing multi-specific antibody therapies for potential treatment of lung and gastrointestinal cancers as well as geographic atrophy. Another new partner, CDR-Life Inc., which is likewise headquartered in Switzerland, also focuses on the latter indication. On the other hand, Boehringer’s new cooperation with the British company Enara Bio Ltd. aims to discover novel antigens for future cancer immunotherapies.
With Click Therapeutics, the group is pursuing the development of a digital therapeutic for the treatment of schizophrenia. Boehringer signed an agreement to acquire NBE-Therapeutics AG in the area of oncology and lastly, Boehringer negotiated the acquisition of contract manufacturer Labor Dr. Merk & Kollegen GmbH.
twitter.com/Boehringer
www.boehringer-ingelheim.com
Headcount: 51,944
Year Established: 1989
Pharma Revenues: $17,705 (+3%)
Net Income: $3,761 (+13)
R&D: $3,696 (+7%)
TOP SELLING DRUGS
Drug | Indication | 2020 Sales | (+/-%) |
Jardiance | Diabetes, type 2 | $3,015 | 15% |
Ofev | Idiopathic pulmonary fibrosis | $2,498 | 38% |
Spirivia | COPD, asthma | $2,180 | -13% |
Trajenta/Jentadueto | Diabetes, Type 2 | $1,838 | -3% |
Pradaxa | Atrial fibrillation | $1,814 | -2% |
In 2020, Boehringer Ingelheim’s pharma revenue rose 3% to $17,705 million despite the Covid-19 pandemic. The company’s research focuses on cardiovascular and metabolic diseases, oncology, respiratory diseases, immunology, diseases of the central nervous system (CNS) and retinal health. Its major emphasis is on the development of medicines and new approaches and therapies to prevent, detect and treat chronic diseases.
The type 2 diabetes medicine jardiance, which also reduces the risk of cardiovascular diseases for type 2 diabetics with pre-existing cardiovascular conditions, was the group’s biggest selling Human Pharma product for the second consecutive year.
At the same time, ofev, which is used for the treatment of the rare respiratory disease idiopathic pulmonary fibrosis and increasingly also in a further indication—systemic sclerosis with interstitial lung disease—registered especially strong growth.
Three other products also played a significant role in Boehringer’s success: Spiriva, which is used for the treatment of chronic obstructive pulmonary disease (COPD) as well as asthma, Trajenta, which is used for treatment of type 2 diabetes, and pradaxa, which is used to prevent strokes in patients with atrial fibrillation and for the prevention and treatment of thromboembolic disorders.
In positive pipeline news, the European Commission approved an additional indication for Nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). The approval came after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.
Also, the U.S. FDA recently granted Fast Track status to Boehringer and Zealand Pharma’s GLP-1/glucagon dual antagonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH). BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis with and without diabetes. The primary endpoint of the trial is the histological improvement of steatohepatitis without worsening of fibrosis after 48 weeks of treatment.
Still, not all projects can be completed successfully: In 2020, Boehringer and Bridge Biotherapeutics mutually agreed on the termination of the collaboration on an autotaxin inhibitor for fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IPF).
In 2020, Boehringer reinforced its position in the area of immunoncology therapies by acquiring shares in the Canadian company Northern Biologics Inc., which was subsequently renamed BI IO Canada Inc. The group also expanded its portfolio of collaborations and partnerships: In the past year, Boehringer entered into new partnerships which include relationships with the U.S. firm Mirati Therapeutics, Inc., which is investigating the use of “PAN-KRAS” inhibitors in the fight against tumors, and with the Swiss company Numab Therapeutics AG, with the goal of developing and commercializing multi-specific antibody therapies for potential treatment of lung and gastrointestinal cancers as well as geographic atrophy. Another new partner, CDR-Life Inc., which is likewise headquartered in Switzerland, also focuses on the latter indication. On the other hand, Boehringer’s new cooperation with the British company Enara Bio Ltd. aims to discover novel antigens for future cancer immunotherapies.
With Click Therapeutics, the group is pursuing the development of a digital therapeutic for the treatment of schizophrenia. Boehringer signed an agreement to acquire NBE-Therapeutics AG in the area of oncology and lastly, Boehringer negotiated the acquisition of contract manufacturer Labor Dr. Merk & Kollegen GmbH.